查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1477923

来那度胺市场- 依类型（5mg、10mg、15mg、25mg 胶囊）、应用（多发性骨髓瘤[MM]、骨髓增生异常综合症[MDS]）、最终用户（医院、癌症治疗中心、研究机构） - 全球预测，2024 年 - 2032

Lenalidomide Market - By Type (5mg, 10mg, 15mg, 25mg Capsules), Application (Multiple Myeloma [MM], Myelodysplastic Syndromes [MDS]), End-user (Hospitals, Cancer Treatment Centers, Research Institutes) - Global Forecast, 2024 - 2032
出版日期: | 出版商: Global Market Insights Inc. | 英文 110 Pages | 商品交期: 2-3个工作天内

价格
简介目录

在血液疾病发病率上升、药物输送技术进步以及新型製剂推出的推动下，来那度胺市场规模预计在 2024 年至 2032 年期间将以 5.1% 的复合年增长率增长。

血液系统疾病，包括各种类型的血癌，如多发性骨髓瘤、骨髓增生异常综合症和套细胞淋巴瘤，在世界各地普遍存在。据估计，到2030年，全球血液恶性肿瘤病例总数预计将达到460万例。随着血液疾病发生率持续上升，对来那度胺等有效治疗方案的需求也随之增加。为此，製药公司大力专注于开发创新疗法，以满足血液恶性肿瘤患者未满足的医疗需求，这将促进市场成长。此外，诊断技术的进步也提高了疾病检出率，从而实现更早的诊断和治疗。

整个市场分为类型、应用程式、最终用户和区域。

到2032 年，来那度胺15 毫克胶囊型细分市场的行业规模将创下5.3% 的复合年增长率，因为它们提供了方便且标准化的剂型，有助于根据患者需求进行精确给药和剂量调整。此外，15 mg 胶囊具有增强的生物利用度和药物动力学特性，可确保最佳的药物暴露和疗效。因此，製药公司越来越关注 15 毫克胶囊製剂的开发和商业化。

从应用来看，到2032 年，骨髓增生异常综合症(MDS) 领域的来那度胺市场预计将以4.9% 的复合年增长率快速增长。因为它提供了巨大的临床益处，包括改善红血球输注独立性和延长整体存活期。随着临床试验和研究计划的重点是优化基于来那度胺的 MDS 治疗方案，该领域预计将出现强劲增长。

在人口快速成长以及血液恶性肿瘤盛行率不断上升的推动下，2024年至2032年亚太地区来那度胺市场规模预计将达到5.5%的复合年增长率。此外，有利的监管政策和不断扩大的医疗基础设施也让人们对癌症护理的认识不断增强。随着製药公司越来越注重扩大在该地区新兴市场的业务，该行业将实现显着成长。

目录

第 1 章：方法与范围

第 2 章：执行摘要

第 3 章：产业洞察

  • 产业生态系统分析
  • 产业影响力
    • 成长动力
      • 骨髓瘤盛行率增加
      • 开发血癌新治疗方案
      • 製药公司之间的合作激增
    • 产业陷阱与挑战
      • 与来那度胺相关的不良反应
  • 成长潜力分析
  • 监管环境
  • 波特的分析
  • PESTEL分析

第 4 章：竞争格局

  • 介绍
  • 公司矩阵分析
  • 竞争定位矩阵
  • 战略仪錶板

第 5 章：市场估计与预测：按类型，2018 - 2032

  • 主要趋势
  • 5毫克胶囊
  • 10毫克胶囊
  • 15毫克胶囊
  • 25毫克胶囊

第 6 章：市场估计与预测：按应用分类，2018 年 - 2032 年

  • 主要趋势
  • 多发性骨髓瘤 (MM)
  • 骨髓增生异常症候群（MDS）
  • 其他应用

第 7 章：市场估计与预测：按最终用户划分，2018 年 - 2032 年

  • 主要趋势
  • 医院
  • 癌症治疗中心
  • 研究机构

第 8 章：市场估计与预测：按地区划分，2018 年 - 2032 年

  • 主要动向：按地区
  • 北美洲
    • 我们
    • 加拿大
  • 欧洲
    • 德国
    • 英国
    • 法国
    • 西班牙
    • 义大利
    • 欧洲其他地区
  • 亚太地区
    • 日本
    • 中国
    • 印度
    • 澳洲
    • 亚太地区其他地区
  • 拉丁美洲
    • 巴西
    • 墨西哥
    • 拉丁美洲其他地区
  • 中东和非洲
    • 南非
    • 沙乌地阿拉伯
    • 中东和非洲其他地区

第 9 章：公司简介

  • Accord Healthcare
  • Cipla
  • Deva Pharma
  • Dr. Reddy's Laboratories Ltd.
  • Glenmark Pharmaceuticals
  • Hetero
  • Hikma Pharmaceuticals
  • Lupin Limited
  • Sun Pharmaceutical Industries Ltd.
  • Teva Pharmaceutical Industries Ltd.
  • Torrent Pharmaceuticals Ltd.
  • Viatris Inc.
简介目录
Product Code: 8286

Lenalidomide Market size is expected to grow at 5.1% CAGR during 2024-2032, driven by rising incidence of hematological disorders, advancements in drug delivery technologies, and the introduction of novel formulations.

Hematological disorders, including various types of blood cancers like multiple myeloma, myelodysplastic syndromes, and mantle cell lymphoma are prevalent worldwide. As per estimates, globally, the total number of hematological malignancy cases is projected to reach 4.6 million by 2030. Rapidly aging population, exposure to environmental carcinogens, and lifestyle changes are contributing to the growing burden of these diseases. As the incidence of hematological disorders continues to rise, there is a corresponding increase in the demand for effective treatment options like lenalidomide. To that end, the strong focus of the pharmaceutical companies on developing innovative therapies to address the unmet medical needs of patients with hematological malignancies will boost the market growth. Moreover, advancements in diagnostic techniques are also improving disease detection rate, leading to earlier diagnosis and treatment initiation.

The overall market is classified into type, application, end-user and region.

Lenalidomide industry size from the 15 mg capsules type segment is set to record 5.3% CAGR through 2032, as they offer a convenient and standardized dosage form, facilitating precise administration and dosage adjustments as per patient requirements. Moreover, 15 mg capsules exhibit enhanced bioavailability and pharmacokinetic properties for ensuring optimal drug exposure and efficacy. As a result, pharmaceutical companies are increasingly focusing on the development and commercialization of 15 mg capsule formulations.

By application, the lenalidomide market from the myelodysplastic syndromes (MDS) segment is poised to grow rapidly at 4.9% CAGR till 2032. Lenalidomide has emerged as a standard-of-care therapy for patients with MDS as it offers substantial clinical benefits, including improved red blood cell transfusion independence and prolonged overall survival. With ongoing clinical trials and research initiatives focusing on optimizing lenalidomide-based regimens for MDS treatment, the segment is expected to witness robust growth.

Asia Pacific lenalidomide market size is set to witness 5.5% CAGR from 2024 to 2032, driven by the burgeoning population coupled with the increasing prevalence of hematological malignancies. Moreover, favorable regulatory policies and the expanding healthcare infrastructure have made way for the growing awareness about cancer care. With pharmaceutical companies increasingly focusing on expanding their presence in emerging markets within the region, the industry will record significant growth.

Table of Contents

Chapter 1 Methodology & Scope

  • 1.1 Market scope & definitions
  • 1.2 Base estimates & calculations
  • 1.3 Data collection
  • 1.4 Forecast parameters
  • 1.5 Data validation
  • 1.6 Data sources
    • 1.6.1 Primary
    • 1.6.2 Secondary
      • 1.6.2.1 Paid sources
      • 1.6.2.2 Public sources

Chapter 2 Executive Summary

  • 2.1 Industry 360 degree synopsis

Chapter 3 Industry Insights

  • 3.1 Industry ecosystem analysis
  • 3.2 Industry impact forces
    • 3.2.1 Growth drivers
      • 3.2.1.1 Increase in prevalence of myeloma
      • 3.2.1.2 Development of novel treatment option for blood cancer
      • 3.2.1.3 Surge in collaboration between pharmaceutical companies
    • 3.2.2 Industry pitfalls & challenges
      • 3.2.2.1 Adverse effects associated with lenalidomide
  • 3.3 Growth potential analysis
  • 3.4 Regulatory landscape
  • 3.5 Porter's analysis
    • 3.5.1 Supplier power
    • 3.5.2 Buyer power
    • 3.5.3 Threat of new entrants
    • 3.5.4 Threat of substitutes
    • 3.5.5 Industry rivalry
  • 3.6 PESTEL analysis

Chapter 4 Competitive Landscape, 2023

  • 4.1 Introduction
  • 4.2 Company matrix analysis
  • 4.3 Competitive positioning matrix
  • 4.4 Strategic dashboard

Chapter 5 Market Estimates and Forecast, By Type, 2018 - 2032 ($ Mn)

  • 5.1 Key trends
  • 5.2 5mg capsules
  • 5.3 10mg capsules
  • 5.4 15mg capsules
  • 5.5 25mg capsules

Chapter 6 Market Estimates and Forecast, By Application, 2018 - 2032 ($ Mn)

  • 6.1 Key trends
  • 6.2 Multiple myeloma (MM)
  • 6.3 Myelodysplastic syndromes (MDS)
  • 6.4 Other applications

Chapter 7 Market Estimates and Forecast, By End-User, 2018 - 2032 ($ Mn)

  • 7.1 Key trends
  • 7.2 Hospitals
  • 7.3 Cancer treatment centers
  • 7.4 Research institutes

Chapter 8 Market Estimates and Forecast, By Region, 2018 - 2032 ($ Mn)

  • 8.1 Key trends, by region
  • 8.2 North America
    • 8.2.1 U.S.
    • 8.2.2 Canada
  • 8.3 Europe
    • 8.3.1 Germany
    • 8.3.2 UK
    • 8.3.3 France
    • 8.3.4 Spain
    • 8.3.5 Italy
    • 8.3.6 Rest of Europe
  • 8.4 Asia Pacific
    • 8.4.1 Japan
    • 8.4.2 China
    • 8.4.3 India
    • 8.4.4 Australia
    • 8.4.5 Rest of Asia Pacific
  • 8.5 Latin America
    • 8.5.1 Brazil
    • 8.5.2 Mexico
    • 8.5.3 Rest of Latin America
  • 8.6 Middle East and Africa
    • 8.6.1 South Africa
    • 8.6.2 Saudi Arabia
    • 8.6.3 Rest of Middle East and Africa

Chapter 9 Company Profiles

  • 9.1 Accord Healthcare
  • 9.2 Cipla
  • 9.3 Deva Pharma
  • 9.4 Dr. Reddy's Laboratories Ltd.
  • 9.5 Glenmark Pharmaceuticals
  • 9.6 Hetero
  • 9.7 Hikma Pharmaceuticals
  • 9.8 Lupin Limited
  • 9.9 Sun Pharmaceutical Industries Ltd.
  • 9.10 Teva Pharmaceutical Industries Ltd.
  • 9.11 Torrent Pharmaceuticals Ltd.
  • 9.12 Viatris Inc.